Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold
June 29, 2026 6:00 AM EDT
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 millionTheravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other monetization of ampreloxetine within the next ten yearsTransaction follows a comprehensive strategic alternatives review conducted by the Company's Strategic Review Committee and Board of DirectorsTransaction expected to close in the second half... More
June 29, 2026 6:00 AM EDT
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks net capital at risk Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected... More
